OR76. The Roles of Growth Differentiation Factor-15 for Prediction of Major Adverse Cardiac Event among Patients with Acute Myocardial Infarction

Abstract Background and Aims Growth Differentiation Factor-15 (GDF-15) is a systemic inflammation marker that has emerged as a biomarker that capable to predicting cardiovascular events. Recent studies suggest that GDF-15 is elevated in patients with acute myocardial infarction, but the prognostic remains incompletely defined. This study aimed to investigate the difference between high and low GDF-15 levels with major cardiac adverse events (MACE) in patients with acute myocardial infarction. Methods and Results This cohort study was conducted with total of 64 acute myocardial infarction patients. GDF-15 was measured at admission and clinical data and 3 months follow up events was registered. MACE at hospitalization occurred in 43.75% of patients, whereas MACE at three months of observation occurred in 18.6% of patients. After adjustment multivariate analysis, higher levels of GDF-15 was independently associated with risk of MACE at 3 months follow up (OR 1.501; p = 0.003). The cut-off point value of GDF-15 was obtained 2256 pg/mL (AUC 0.848; 95% p = 0.001). Risk model with Kapplan Meier showed significant association between high GDF-15 levels (≥ 2256 pg/mL) and the incidence of MACE during hospitalization (HR 2.492; 95% CI 1.126-5.518; p = 0.0024) and MACE at 3 months follow up (HR 14.693; 95% CI 1.877-115.047; p < 0.001) Conclusion GDF-15 was significantly associated with the risk of MACE at hospitalization and at 3 months of observation after acute myocardial infarction